Open AccessJournal Article
Comparison of Pharmacological Activities of Buprenorphine and Norbuprenorphine: Norbuprenorphine Is a Potent Opioid Agonist
TLDR
The binding of norBUP to opioid and nociceptin/orphanin FQ (ORL1) receptors, and its effects on [(35)S]guanosine-5'-O-(gamma-thio)triphosphate ([(35]S]GTP gamma S) binding mediated by opioid or ORL1 receptors are described and highlighted.Abstract:
Buprenorphine (BUP) is an oripavine analgesic that is beneficial in the maintenance treatment of opiate-dependent individuals. Although BUP has been studied extensively, relatively little is known about norbuprenorphine (norBUP), a major dealkylated metabolite of BUP. We now describe the binding of norBUP to opioid and nociceptin/orphanin FQ (ORL1) receptors, and its effects on [35S]guanosine-5′-O-(γ-thio)triphosphate ([35S]GTPγS) binding mediated by opioid or ORL1 receptors and in the mouse acetic acid writhing test. Chinese hamster ovary cells stably transfected with each receptor were used for receptor binding and [35S]GTPγS binding. NorBUP exhibited high affinities for μ-, δ-, and κ-opioid receptors withKi values in the nanomolar or subnanomolar range, comparable to those of BUP. NorBUP and BUP had low affinities for the ORL1 receptor with Ki values in the micromolar range. In the [35S]GTPγS binding assay, norBUP displayed characteristics distinct from BUP. At the δ-receptor, norBUP was a potent full agonist, yet BUP had no agonist activity and antagonized actions of norBUP and DPDPE. At μ- and κ-receptors, both norBUP and BUP were potent partial agonists, with norBUP having moderate efficacy and BUP having low efficacy. At the ORL1 receptor, norBUP was a full agonist with low potency, while BUP was a potent partial agonist. In the writhing test, BUP and norBUP both suppressed writhing in an efficacious and dose-dependent manner, giving A50 values of 0.067 and 0.21 mg/kg, s.c., respectively. These results highlight the similarities and differences between BUP and norBUP, each of which may influence the unique pharmacological profile of BUP.read more
Citations
More filters
Journal ArticleDOI
Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: Role of circulating active metabolites
Bojan Lalovic,Bojan Lalovic,Bojan Lalovic,Evan D. Kharasch,Evan D. Kharasch,Evan D. Kharasch,Christine Hoffer,Christine Hoffer,Christine Hoffer,Linda J. Risler,Linda J. Risler,Linda J. Risler,Lee-Yuan Liu-Chen,Lee-Yuan Liu-Chen,Lee-Yuan Liu-Chen,Danny D. Shen,Danny D. Shen,Danny D. Shen +17 more
TL;DR: In vitro experiments suggest that circulating metabolites of oxycodone are opioid receptor agonists and that the O‐demethylated metabolite oxymorphone toward the clinical effects of the parent drug is significant.
Journal ArticleDOI
Buprenorphine: a unique drug with complex pharmacology.
Kabirullah Lutfy,Alan Cowan +1 more
TL;DR: Evidence is provided demonstrating that the ORL-1 receptor plays a functional role not only in the antinociceptive effect of buprenorphine but also in other actions of the drug as well.
Journal ArticleDOI
Current knowledge of buprenorphine and its unique pharmacological profile.
Joseph V. Pergolizzi,Anna Maria Aloisi,Albert Dahan,Joerg Filitz,Richard M. Langford,Rudolf Likar,Sebastiano Mercadante,Bart Morlion,Robert B. Raffa,Rainer Sabatowski,Paola Sacerdote,Luis Torres,Avi A. Weinbroum +12 more
TL;DR: Buprenorphine exhibits a pronounced antihyperalgesic effect that might indicate potential advantages in the treatment of neuropathic pain, and its favorable safety profile and proven efficacy in severe pain and favorable tolerability mean that it can be considered a safe and effective option for treating chronic cancer and noncancer pain.
Journal ArticleDOI
Buprenorphine-Induced Antinociception Is Mediated by μ-Opioid Receptors and Compromised by Concomitant Activation of Opioid Receptor-Like Receptors
Kabirullah Lutfy,Shoshana Eitan,Camron D. Bryant,Yu C. Yang,Nazli Saliminejad,Wendy Walwyn,Brigitte L. Kieffer,Hiroshi Takeshima,F. Ivy Carroll,Nigel T. Maidment,Christopher J. Evans +10 more
TL;DR: The results indicate that the antinociceptive effect of buprenorphine in mice is μ-opioid receptor-mediated yet severely compromised by concomitant activation of ORL-1 receptors.
Journal ArticleDOI
Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists.
Alexander Gillis,Arisbel B. Gondin,Andrea Kliewer,Julie Sanchez,Julie Sanchez,Herman D. Lim,Claudia Alamein,Preeti Manandhar,Marina Santiago,Sebastian Fritzwanker,Frank Schmiedel,Timothy A. Katte,Tristan A. Reekie,Natasha L. Grimsey,Michael Kassiou,Barrie Kellam,Cornelius Krasel,Michelle L. Halls,Mark Connor,J. Robert Lane,Stefan Schulz,MacDonald J. Christie,Meritxell Canals,Meritxell Canals +23 more
TL;DR: It is shown that the low intrinsic efficacy of opioid ligands can explain an improved side effect profile and suggest a possible alternative mechanism underlying the improved therapeutic windows described for new opioid liganded, which should be taken into account for future descriptions of ligand action at this important therapeutic target.
References
More filters
Journal ArticleDOI
Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.
TL;DR: The analysis described shows K I does not equal I 50 when competitive inhibition kinetics apply; however, K I is equal to I 50 under conditions of either noncompetitive or uncompetitive kinetics.
Journal ArticleDOI
Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor.
Jean-Claude Meunier,Catherine Mollereau,Lawrence Toll,Lawrence Toll,Charles Suaudeau,Christiane Moisand,Paul Alvinerie,Jean-Luc Butour,Jean-Claude Guillemot,Pascual Ferrara,Bernard Monsarrat,Honoré Mazarguil,Gilbert Vassart,Marc Parmentier,Jean Costentin +14 more
TL;DR: Data indicate that the newly discovered heptadecapeptide is an endogenous agonist of the ORL1 receptor and that it may be endowed with pro-nociceptive properties.
Journal ArticleDOI
Orphanin FQ: a neuropeptide that activates an opioidlike G protein-coupled receptor.
Rainer K. Reinscheid,Hans Peter Nothacker,Anne Bourson,Ali Ardati,Robert Henningsen,James R. Bunzow,David K. Grandy,Hanno Langen,Frederick J. Monsma,Olivier Civelli +9 more
TL;DR: Orphanin FQ may act as a transmitter in the brain by modulating nociceptive and locomotor behavior by binding to its receptor in a saturable manner and with high affinity.
Journal ArticleDOI
Cloning of a delta opioid receptor by functional expression
TL;DR: A complementary DNA clone encoding a functional delta opioid receptor has been identified and shows homology to G protein-coupled receptors, in particular the receptors for somatostatin, angiotensin, and interleukin-8.
Journal Article
Molecular cloning and functional expression of a mu-opioid receptor from rat brain.
TL;DR: Results suggest that this mu-opioid receptor is functionally coupled to the inhibition of adenylyl cyclase, and is a mu-type opioid receptor, which is designated MOR-1.